Personalis (NASDAQ:PSNL) Sees Strong Trading Volume – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL) shares saw unusually-high trading volume on Friday . Approximately 6,060,111 shares were traded during mid-day trading, an increase of 422% from the previous session’s volume of 1,161,555 shares.The stock last traded at $8.39 and had previously closed at $7.93.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PSNL. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. BTIG Research increased their price objective on Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Personalis in a research note on Wednesday, November 5th. Needham & Company LLC upped their target price on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.57.

Personalis Stock Performance

The company has a market capitalization of $759.24 million, a PE ratio of -9.72 and a beta of 1.99. The stock has a 50 day moving average price of $9.03 and a two-hundred day moving average price of $7.02.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. Sell-side analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in Personalis in the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Personalis in the second quarter worth $34,000. BNP Paribas Financial Markets lifted its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of Personalis during the 1st quarter worth $47,000. Finally, Alpha Wealth Funds LLC acquired a new position in Personalis in the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.